BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 103 filers reported holding BIOXCEL THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $358,438 | -46.7% | 141,675 | +40.3% | 0.00% | – |
| Q2 2023 | $672,454 | +236.4% | 100,969 | +842.6% | 0.00% | – |
| Q1 2023 | $199,886 | +33.3% | 10,712 | -15.4% | 0.00% | – |
| Q3 2022 | $150,000 | -90.8% | 12,666 | -83.8% | 0.00% | -100.0% |
| Q1 2022 | $1,631,000 | +242.6% | 78,004 | +232.8% | 0.00% | – |
| Q4 2021 | $476,000 | -25.2% | 23,442 | +11.9% | 0.00% | – |
| Q3 2021 | $636,000 | -45.4% | 20,954 | -47.7% | 0.00% | – |
| Q2 2021 | $1,165,000 | -56.6% | 40,098 | -35.6% | 0.00% | -100.0% |
| Q1 2021 | $2,687,000 | -35.6% | 62,247 | -31.1% | 0.00% | -33.3% |
| Q4 2020 | $4,175,000 | -40.2% | 90,385 | -43.8% | 0.00% | -25.0% |
| Q3 2020 | $6,977,000 | +51.2% | 160,921 | +84.9% | 0.00% | +33.3% |
| Q2 2020 | $4,614,000 | +1830.5% | 87,033 | +713.5% | 0.00% | – |
| Q1 2020 | $239,000 | – | 10,698 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 60,000 | $151,800 | 0.16% |
| XTX Topco Ltd | 33,605 | $85,021 | 0.02% |
| Beacon Pointe Advisors, LLC | 301,735 | $763,390 | 0.01% |
| AllSquare Wealth Management LLC | 4,527 | $11,453 | 0.01% |
| Virtus ETF Advisers LLC | 4,646 | $11,754 | 0.01% |
| Y-Intercept (Hong Kong) Ltd | 27,553 | $69,709 | 0.01% |
| SeaCrest Wealth Management, LLC | 16,550 | $41,872 | 0.01% |
| Hennion & Walsh Asset Management, Inc. | 33,940 | $85,868 | 0.01% |
| Cutler Group LLC / CA | 4,000 | $50 | 0.01% |
| Capital Investment Advisory Services, LLC | 17,991 | $45,517 | 0.00% |